30 closest matches · ranked by relevance
May-Thurner Syndrome · Deep Vein Thrombosis · Chronic Venous Insufficiency
Primary: Safety - Number of Participants Free From Major Adverse Events (MAEs) at 30 Days — 157 Participants
Symptomatic Venous Outflow Obstruction in the Iliofemoral Vein
Primary: Number of Participants With 30-day Freedom From Major Adverse Events — 232 Participants — p=<0.0001
Chronic Venous Disorder · Venous Outflow Obstruction · Symptomatic Venous Outflow Obstruction of Iliofemoral Vein
Primary: Number of Participants With Major Adverse Events (MAE) — 0; 0; 0; 0 Participants
Coronary Heart Disease
Primary: Brachial Flow Velocity — 21.0 cm/sec
Iliofemoral Venous Obstruction
Primary: Primary Patency — 162 Participants — p=<0.0001
May-Thurner Syndrome · Peripheral Vascular Disease · Venous Disease
Primary: Number of Participants With Primary Patency of the Venous Stent at 12 Months Post-Index Procedure — 128 Participants — p=0.0001
Chronic Venous Insufficiency
Primary: Change in the Quality of Life as Measured by CIVIQ-20 — 12.2 score on a scale
May-Thurner Syndrome
Primary: Left Common Iliac Vein Diameter — 7.5; 7.7 Millimeters (mm)
Venous Thrombosis
Primary: The Primary Effective Endpoint: Percent of Treated Vessel(s) With ≥ 75% Venous Thrombus Reduction in Modified Marder Score (From Pre-JETi to Final) — 84.5 percentage of…
Chronic Venous Insufficiency
Primary: Safety: AEs, SAEs, ADEs, SADEs, UADEs — 0; 0; 0; 0 Events
Venous Thromboembolism · Venous Thrombosis
Primary: Number of Patients With Asymptomatic Venous Thrombosis of Lower Limbs as Detected by Duplex Ultrasound — 1; 34 Participants — p=<0.001
Venous Thrombosis · Deep Vein Thrombosis
Primary: Rate of Deep Vein Thrombosis — 14; 15; 9; 12 participants — p=0.785
Peripheral Arterial Disease · Claudication
Primary: Major Adverse Event Rate at 9 Months — 4.0 percentage of participants
Peripheral Arterial Disease
Primary: Walking Endurance — -14; 35 Meters
Acute Deep Vein Thrombosis
Primary: 2-year Change in Villalta Score — -1.5; -0.5 units on a scale — p=0.34
Venous Insufficiency
Primary: Primary Effectiveness Objective — 53; 66 Treated IPVs
Deep Vein Thrombosis · Venous Thrombosis · Postphlebitic Syndrome
Primary: Cumulative Incidence of Post-Thrombotic Syndrome (Villalta Scale) — 157; 171 Participants — p=0.56
Peripheral Artery Disease · PAD · Claudication
Primary: Rate of Clinically Driven Target Lesion Revascularization (TLR) — 4.0; 8.2 % probablity of clinically driven TLR
Critical Limb Ischemia
Primary: Amputation-free Survival — 50.7 percentage of participants
Venous Leg Ulcer
Primary: Change From Baseline in Wound Perimeter — 29.36; 43.64 mm
Deep Venous Thrombosis
Primary: Incidence of Post-thrombotic Syndrome (PTS) — 44; 37 participants — p=.58
Peripheral Artery Disease
Primary: Composite of Major Adverse Events (MAE) Defined as the Occurrence of In-hospital Myocardial Infarction (MI) or Target Segment Revascularization, Target Limb Loss, or…
Surgical Wound
Primary: Time to Ambulation (TTA) — 2.8; 6.1 hours
Venous Thromboembolism
Primary: Percentage of Participants With Composite Endpoint of Venous Thromboembolism [VTE] (Any Deep Vein Thrombosis [DVT], Non Fatal Pulmonary Embolism [PE]) and VTE-related…
Varicose Veins
Primary: Change in Patient-reported Symptoms of Varicose Veins (VVSymQ Score) — 2.13; 4.63; 5.68; 4.87 units on a scale — p==0.0001
Superficial Vein Thrombosis
Primary: Rate of Objectively Confirmed VTE Complications — 7; 4 Participants — p=0.0252
Peripheral Arterial Disease
Primary: Composite of Major Adverse Events (MAEs) — 2.3 percentage of subjects experiencing MAE — p=<0.001
Hip Arthroscopy · Nerve Block
Primary: Pain Score Change — 3; 1.72 change in score on a scale
Varicose Veins
Primary: Change in Patient-Reported Symptoms of Varicose Veins (VVSymQ Score) — -2.00; -5.34; -6.01; -5.06 units on a scale — p=<0.0001
IV Access
Primary: Number of Participants With Successful Cannulation of the Internal Jugular Vein — 34 Participants